Nomura Holdings Inc. Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Nomura Holdings Inc. bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 3,706 shares of the medical research company’s stock, valued at approximately $857,000.

Several other hedge funds have also added to or reduced their stakes in the business. HighPoint Advisor Group LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $404,000. PNC Financial Services Group Inc. grew its holdings in shares of IQVIA by 4.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 43,380 shares of the medical research company’s stock worth $10,037,000 after purchasing an additional 1,943 shares during the last quarter. ICA Group Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth $77,000. Goldman Sachs Group Inc. raised its holdings in IQVIA by 21.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 837,865 shares of the medical research company’s stock valued at $193,865,000 after buying an additional 148,568 shares during the last quarter. Finally, Centaurus Financial Inc. purchased a new stake in IQVIA during the 4th quarter valued at $169,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $214.19 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market cap of $39.03 billion, a P/E ratio of 29.26, a P/E/G ratio of 1.94 and a beta of 1.53. The business’s 50 day moving average price is $225.93 and its 200-day moving average price is $230.17. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on IQV shares. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 target price for the company. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. Finally, Robert W. Baird cut their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $258.40.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.